TY - JOUR
T1 - Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance
AU - Brouard, Sophie
AU - Mansfield, Elaine
AU - Braud, Christophe
AU - Li, Li
AU - Giral, Magali
AU - Hsieh, Szu Chuan
AU - Baeten, Dominique
AU - Zhang, Meixia
AU - Ashton-Chess, Joanna
AU - Braudeau, Cécile
AU - Hsieh, Frank
AU - Dupont, Alexandre
AU - Pallier, Annaik
AU - Moreau, Anne
AU - Louis, Stéphanie
AU - Ruiz, Catherine
AU - Salvatierra, Oscar
AU - Soulillou, Jean Paul
AU - Sarwal, Minnie
PY - 2007/9/25
Y1 - 2007/9/25
N2 - Long-term allograft survival generally requires lifelong immunosuppression (IS). Rarely, recipients display spontaneous "operational tolerance" with stable graft function in the absence of IS. The lack of biological markers of this phenomenon precludes identification of potentially tolerant patients in which IS could be tapered and hinders the development of new tolerance-inducing strategies. The objective of this study was to identify minimally invasive blood biomarkers for operational tolerance and use these biomarkers to determine the frequency of this state in immunosuppressed patients with stable graft function. Blood gene expression profiles from 75 renal-transplant patient cohorts (operational tolerance/acute and chronic rejection/stable graft function on IS) and 16 healthy individuals were analyzed. A subset of samples was used for microarray analysis where three-class comparison of the different groups of patients identified a "tolerant footprint" of 49 genes. These biomarkers were applied for prediction of operational tolerance by microarray and real-time PCR in independent test groups. Thirty-three of 49 genes correctly segregated tolerance and chronic rejection phenotypes with 99% and 86% specificity. The signature is shared with 1 of 12 and 5 of 10 stable patients on triple IS and low-dose steroid monotherapy, respectively. The gene signature suggests a pattern of reduced costimulatory signaling, immune quiescence, apoptosis, and memory T cell responses. This study identifies in the blood of kidney recipients a set of genes associated with operational tolerance that may have utility as a minimally invasive monitoring tool for guiding IS titration. Further validation of this tool for safe IS minimization in prospective clinical trials is warranted.
AB - Long-term allograft survival generally requires lifelong immunosuppression (IS). Rarely, recipients display spontaneous "operational tolerance" with stable graft function in the absence of IS. The lack of biological markers of this phenomenon precludes identification of potentially tolerant patients in which IS could be tapered and hinders the development of new tolerance-inducing strategies. The objective of this study was to identify minimally invasive blood biomarkers for operational tolerance and use these biomarkers to determine the frequency of this state in immunosuppressed patients with stable graft function. Blood gene expression profiles from 75 renal-transplant patient cohorts (operational tolerance/acute and chronic rejection/stable graft function on IS) and 16 healthy individuals were analyzed. A subset of samples was used for microarray analysis where three-class comparison of the different groups of patients identified a "tolerant footprint" of 49 genes. These biomarkers were applied for prediction of operational tolerance by microarray and real-time PCR in independent test groups. Thirty-three of 49 genes correctly segregated tolerance and chronic rejection phenotypes with 99% and 86% specificity. The signature is shared with 1 of 12 and 5 of 10 stable patients on triple IS and low-dose steroid monotherapy, respectively. The gene signature suggests a pattern of reduced costimulatory signaling, immune quiescence, apoptosis, and memory T cell responses. This study identifies in the blood of kidney recipients a set of genes associated with operational tolerance that may have utility as a minimally invasive monitoring tool for guiding IS titration. Further validation of this tool for safe IS minimization in prospective clinical trials is warranted.
KW - Genomics
KW - Immunosuppression titration
KW - Kidney transplantation
KW - Microarray
KW - Tolerant
UR - http://www.scopus.com/inward/record.url?scp=34848857054&partnerID=8YFLogxK
U2 - 10.1073/pnas.0705834104
DO - 10.1073/pnas.0705834104
M3 - Article
C2 - 17873064
AN - SCOPUS:34848857054
SN - 0027-8424
VL - 104
SP - 15448
EP - 15453
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 39
ER -